[Articles] Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial

Journal content Created on 04 Jun 2026 The Lancet

• Details
• • All feed content
  • My feed content